iotrolan
Trade name: osmovist
Small moleculeapproved
Approved
Jun 1, 1984
Iotrol, a nonionic dimeric, intrathecal contrast medium for myelography. This agent does not exhibit any cytotoxic effect on human healthy nucleus pulposus (NP) cells. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedJun 1, 1984
Chemistry & pharmacology
Loading structure…
SMILES
CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C2=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C2I- Mol. weight
- 1626.2332 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIotrolan ↗
- NCATS16FL47B687 ↗
- ChEMBLCHEMBL1200555 ↗
Also known as
- 1,3-benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis(methylimino))bis(n,n'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl))-2,4,6-triiodo-
- berlex brand of iotrolan
- dl 3117
- dl 3-117
- dl-3-117
- iotrol
- iotrol
- iotrol
- iotrol
- iotrolan
- iotrolan
- iotrolan
- iotrolan
- iotrolan
- iotrolan
- iotrolan
- iotrolan
- iotrovist
- isovist
- isovist
- isovist 300
- osmovist
- osmovist
- osmovist
- osmovist
- osmovist 190
- osmovist 190
- osmovist 240
- osmovist 240
- schering brand of iotrolan
- zk-39482
- zk-39482